Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
McKinsey
Argus Health
Teva
Julphar
AstraZeneca

Generated: April 26, 2019

DrugPatentWatch Database Preview

ZERVIATE Drug Profile

« Back to Dashboard

When do Zerviate patents expire, and when can generic versions of Zerviate launch?

Zerviate is a drug marketed by Eyevance and is included in one NDA. There are four patents protecting this drug.

This drug has fifteen patent family members in five countries.

The generic ingredient in ZERVIATE is cetirizine hydrochloride. There are thirty-nine drug master file entries for this compound. One hundred and sixty-five suppliers are listed for this compound. Additional details are available on the cetirizine hydrochloride profile page.

Summary for ZERVIATE
Drug patent expirations by year for ZERVIATE
Medical Subject Heading (MeSH) Categories for ZERVIATE
Synonyms for ZERVIATE
(2-(4-((4-Chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)acetic acid
(2-{4-[(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethoxy)acetic acid
(2-{4-[(4-Chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethoxy)acetic acid (2HCl)
[(2-{4-[(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethyl)oxy]acetic acid
[2-[4-[(4-Chlorophenyl)-phenyl methyl]-1-piperazinyl] ethoxy] acetic acid
[2-[4-[(4-chlorophenyl)phenylmethyl] 1-piperazinyl]-ethoxy] acetic acid
[2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]-ethoxy]acetic acid
[2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]acetic acid
110271-EP2284166A1
110271-EP2298415A1
2-(2-(4-((4-Chlorophenyl)(phenyl)methyl)piperazin-1-yl)ethoxy)acetic acid
2-(2-{4-[(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethoxy)acetic acid
2-(2-{4-[(4-chlorophenyl)(phenyl)methyl]piperazino}ethoxy)acetic acid
2-(2-{4-[(4-chlorophenyl)phenylmethyl]piperazinyl}ethoxy)acetic acid
2-[2-[4-[(4-chlorophenyl)-phenyl-methyl]piperazin-1-yl]ethoxy]acetic acid
2-[2-[4-[(4-chlorophenyl)-phenylmethyl]piperazin-1-yl]ethoxy]acetic acid
2-[2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]acetic acid
24161-EP2272832A1
24161-EP2281815A1
24161-EP2295409A1
24161-EP2301933A1
24161-EP2305640A2
24161-EP2311827A1
24161-EP2314590A1
81C510
83881-51-0
83881-52-1 (di-hydrochloride)
A10107
AB0019096
AC-5545
AC1L1E7T
AC1Q768B
Acetic acid, (2-(4-((4-chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)-
Acetic acid, [2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-
AKOS003589059
AKOS021729457
Alerlisin
AN-10906
AN-15756
BBL009968
BCP08787
BCP28477
BDBM22890
Benaday
BPBio1_000469
BRD-A42571354-300-05-4
BRD-A42571354-300-07-0
BSPBio_000425
BSPBio_002302
C-5854
C07778
C21H25ClN2O3
CC0153
Cetiderm (TN)
Cetirizin
Cetirizina
Cetirizina [Spanish]
cetirizine
Cetirizine (INN)
Cetirizine [INN:BAN]
CETIRIZINE HYDROCHLORIDE
CetirizineHydrochloride
Cetirizinum
Cetirizinum [Latin]
Cetrizide
Cetrizine Dihcl
Cetrizine Hcl
Cetryn
CHEBI:3561
CHEMBL1000
CPD001453715
CS-0886
CTK7J5576
D07662
DB00341
DTXSID4022787
EN300-52521
FT-0603001
FT-0654660
GTPL1222
Hitrizin Film Tablet
HMS1539O07
HMS3259D06
HMS3370I19
HMS3393N10
HSDB 7739
HY-17042
I06-0454
J-005737
L000655
Levocetirizine HCl
LS-11409
MCULE-8668839822
MFCD00800721
MolPort-002-506-309
NC00696
NCGC00167781-01
NCGC00167781-02
NCGC00167781-03
NCGC00167781-04
NCGC00167781-07
Prestwick0_000503
Prestwick1_000503
Prestwick2_000503
Prestwick3_000503
RT-007014
SAM002548972
SAM002589989
SBI-0206838.P001
SC-17992
SC-18167
SC-19204
SC-19390
SCHEMBL4176
Setir
SPBio_002346
ST024755
STK711108
TimTec1_002075
U095
Virlix
Xarlin
Z1182332250
Ziptek
Zirtek
ZKLPARSLTMPFCP-UHFFFAOYSA-N
Zyrlex
Zyrtec Syrup
Zyrtec-D

US Patents and Regulatory Information for ZERVIATE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Eyevance ZERVIATE cetirizine hydrochloride SOLUTION/DROPS;OPHTHALMIC 208694-001 May 30, 2017 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Eyevance ZERVIATE cetirizine hydrochloride SOLUTION/DROPS;OPHTHALMIC 208694-001 May 30, 2017 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Eyevance ZERVIATE cetirizine hydrochloride SOLUTION/DROPS;OPHTHALMIC 208694-001 May 30, 2017 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Eyevance ZERVIATE cetirizine hydrochloride SOLUTION/DROPS;OPHTHALMIC 208694-001 May 30, 2017 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

Subscribe to access the full database, or try a Free Trial

Supplementary Protection Certificates for ZERVIATE

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0663828 C300085 Netherlands ➤ Sign Up PRODUCT NAME: LEVOCETIRIZINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER LEVOCETIRINE DIHYDROCHLORIDE; NAT. REGISTRATION NO/DATE: RVG 26770 20011009; FIRST REGISTRATION: DE 49903.00.00 AND 49904.00.00 20010103
0058146 2001C/045 Belgium ➤ Sign Up PRODUCT NAME: DICHLORHYDRATE DE LEVOCETIRIZINE; NAT RER. NO/DATE: 194 IS 90 F3 20011022; FIRST REG.: DE 49903.00.00 20010103
Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
Daiichi Sankyo
Teva
Citi
US Department of Justice
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.